Scarica l'app Stockscreener
12.64
1.10%
-0.14
Precedente Chiudi:
$12.78
Aprire:
$13.06
Volume 24 ore:
1.82M
Relative Volume:
2.22
Capitalizzazione di mercato:
$937.15M
Reddito:
$97.36M
Utile/perdita netta:
$-172.42M
Rapporto P/E:
-5.4995
EPS:
-2.2984
Flusso di cassa netto:
$-188.84M
1 W Prestazione:
+4.55%
1M Prestazione:
+14.29%
6M Prestazione:
-19.44%
1 anno Prestazione:
+51.20%
Intervallo 1D:
$12.49
$13.32
Intervallo di 1 settimana:
$11.90
$13.32
Portata 52W:
$6.92
$18.69
Xencor Inc Stock (XNCR) Company Profile
Nome
Xencor Inc
Settore
Industria
Telefono
626-305-5900
Indirizzo
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
12.64 | 937.15M | 97.36M | -172.42M | -188.84M | -2.2984 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-10-29 | Aggiornamento | Barclays | Underweight → Overweight |
| 2025-09-17 | Ripresa | Barclays | Underweight |
| 2025-09-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-04-21 | Iniziato | William Blair | Outperform |
| 2024-12-12 | Iniziato | Wells Fargo | Overweight |
| 2024-12-02 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | Reiterato | BTIG Research | Buy |
| 2024-02-28 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | Iniziato | BofA Securities | Buy |
| 2022-12-06 | Iniziato | Cowen | Outperform |
| 2022-10-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-02-11 | Iniziato | BMO Capital Markets | Outperform |
| 2022-01-21 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-15 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-02-24 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | Iniziato | Barclays | Underweight |
| 2020-02-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-01-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-11-20 | Ripresa | Guggenheim | Neutral |
| 2019-08-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-08-07 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-04-12 | Iniziato | Guggenheim | Buy |
| 2019-03-27 | Iniziato | Berenberg | Buy |
| 2019-03-15 | Iniziato | Raymond James | Outperform |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-03-28 | Ripresa | Leerink Partners | Outperform |
| 2017-03-02 | Iniziato | Instinet | Neutral |
| 2017-03-02 | Reiterato | Wedbush | Outperform |
| 2016-10-04 | Iniziato | Piper Jaffray | Overweight |
| 2015-12-22 | Iniziato | Canaccord Genuity | Buy |
| 2015-08-05 | Reiterato | MLV & Co | Buy |
| 2015-02-12 | Reiterato | Oppenheimer | Outperform |
| 2015-01-28 | Reiterato | MLV & Co | Buy |
| 2014-07-11 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Xencor Inc Borsa (XNCR) Ultime notizie
Xencor, Inc. Files 8-K: Company Details, Stock Info, and Executive Plan Updates for 2026 - Minichart
Xencor Shareholders Approve Directors, Incentive Plan Amendments - TipRanks
Why (XNCR) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Xencor (NASDAQ: XNCR) investors back 4M-share equity plan boost and all proposals - Stock Titan
Xencor Inc (XNCR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
[144] Xencor Inc SEC Filing - Stock Titan
Insider Sell Alert: Richard Ranieri Sells Shares of Xencor Inc (XNCR) - GuruFocus
Xencor Inc (XNCR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Xencor Inc (XNCR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Xencor Inc (XNCR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Xencor Inc (XNCR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Xencor Inc (XNCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Xencor Inc (XNCR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Director at Xencor (XNCR) sells 7,527 shares under 10b5-1 plan - Stock Titan
Xencor (XNCR) director sells 5,474 shares under Rule 10b5-1 plan - Stock Titan
Xencor (XNCR) director Ranieri sells 5,474 shares under 10b5-1 plan - Stock Titan
Planned share sale by Xencor (XNCR) director under Rule 10b5-1 plan - Stock Titan
Xencor Inc (XNCR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Xencor (XNCR) Stock Draws Fresh Price Target Split As Pipeline Progress Meets Caution - Yahoo Finance
Xencor Inc Stock (US98401F1057): Analyst Views In Focus After Recent Collaboration Momentum - AD HOC NEWS
Understanding Momentum Shifts in (XNCR) - Stock Traders Daily
Xencor (XNCR) Slides 2% as Biotech Sentiment Weakens — Support TestedTRIN Signal - newsline.com
Incyte lymphoma therapy lifts cancer-free survival by 25% in late-stage trial - MSN
Xencor Inc stock (US98401F1057): shares react to Monjuvi first-line lymphoma update and recent Q1 20 - AD HOC NEWS
XNCR Technical Analysis & Stock Price Forecast - Intellectia AI
XNCR Q1 2026 Earnings: Deep Loss Miss as Pipeline Biotech Faces Market SkepticismInterim Report - The Legal Advocate
XNCR Q1 2026 Earnings: Significant EPS Miss Amidst Clinical Development ProgressAnnual Report - newsline.com
XNCR Q1 2026 Earnings: Deeper-than-Expected Loss Highlights Persistent R&D InvestmentEarnings Revision Upgrade - newsline.com
Xencor Inc stock (US98401F1057): shares trade around recent lows as investors digest pipeline and va - AD HOC NEWS
Avoiding Lag: Real-Time Signals in (XNCR) Movement - Stock Traders Daily
XNCR Q1 2026 Earnings: Large EPS Miss Amid Pre-Revenue Status; Stock Gains SlightlyEarnings Acceleration Picks - newsline.com
Xencor Inc. (XNCR) Holds Ground Near $11.31: Key Levels in FocusComposite Profile - Newser
Jefferies Financial Group Inc. Purchases 620,440 Shares of Xencor, Inc. $XNCR - MarketBeat
Xencor, Inc. (XNCR) Competitors - Meyka
Xencor Inc. (XNCR) Holds Near Support as Biotech Sector Shows Mixed SignalsCrowd Entry Points - Newser
Xencor (XNCR) Q1 2026 Underperforms: Key Challenges AheadPro Level Trade Signals - Newser
Xencor’s SWOT analysis: biotech stock faces pipeline execution test - Investing.com
Xencor’s SWOT analysis: biotech stock faces pipeline execution test By Investing.com - Investing.com Canada
Xencor (XNCR) Q1 2026 Disappoints — EPS $-1.71 Below $-0.79 ViewsPopular Trader Picks - Newser
T-cell Engagers Market to Record US$ 58.04 billion by 2035., - openPR.com
Xencor Inc stock (US98401F1057): JPMorgan lifts target while investors eye Q1 2026 update - AD HOC NEWS
Xencor, Inc. $XNCR Shares Sold by UBS Group AG - MarketBeat
EcoR1 reports 2.9% Xencor stake (NASDAQ: XNCR) - Stock Titan
Bank of America Securities Sticks to Their Hold Rating for Xencor (XNCR) - The Globe and Mail
Xencor stock (US98401F1057): Biotech focus on immunotherapy and protein engineering - AD HOC NEWS
Xencor (XNCR) Declines -2.50% Amid Market Weakness 2026-05-14Undervalued Stocks - Newser
TradingKey - TradingKey
Xencor stock (US98401F1057): Biotech innovator in antibody therapies - AD HOC NEWS
Xencor Is Maintained at Neutral by JP Morgan - Moomoo
Bi/Multispecific Drugs in Oncology Analytical Tool Featuring Top DevelopersAmgen, Hoffmann-La Roche, J&J, Xencor, BiocytogenUnlocking New Precision, Immune Activation, and Therapeutic Potential - Yahoo Finance
TD Cowen Maintains Xencor(XNCR.US) With Buy Rating - Moomoo
Xencor Inc Azioni (XNCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):